Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.
暂无分享,去创建一个
J. Albanell | M. Campone | P. Fumoleau | J. Dewar | M. Martín | J. García-Saenz | J. Chang | J. Xu | A. Strasak | S. D. de Haas | S. Limentani | M. Patre | S. de Haas | M. Martín | J. Chang
[1] E. Perez,et al. Phase III, randomized study of trastuzumab emtansine (T-DM1) {+/-} pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study. , 2015 .
[2] Sung-Bae Kim,et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. , 2015, The New England journal of medicine.
[3] N. Harbeck,et al. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Sung-Bae Kim,et al. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.
[5] M. Sliwkowski,et al. Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy , 2013, Clinical Cancer Research.
[6] J. Baselga,et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.
[7] Sung-Bae Kim,et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. , 2012, The New England journal of medicine.
[8] Giulia Bianchi,et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. , 2012, The Lancet. Oncology.
[9] Dan Lu,et al. Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer , 2012, Cancer Chemotherapy and Pharmacology.
[10] M. Sliwkowski,et al. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer , 2011, Breast Cancer Research and Treatment.
[11] J. Ross,et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. , 2009, The oncologist.
[12] John M Lambert,et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. , 2008, Cancer research.
[13] M. Sliwkowski,et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. , 2004, Cancer cell.
[14] C. Compton,et al. AJCC Cancer Staging Manual , 2002, Springer New York.
[15] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[16] M Van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.
[17] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.